bioAffinity Technologies (Nasdaq: BIAF) highlights CyPath Lung trial performance
Rhea-AI Filing Summary
On July 27, 2026, bioAffinity Technologies, Inc. announced publication of a comprehensive clinical review and white paper by its Chief Medical Officer that presents a practical framework for integrating the CyPath® Lung noninvasive test into pulmonary nodule evaluation and lung cancer surveillance across pulmonology, primary care and oncology settings.
The company notes that in a published clinical trial of high-risk patients CyPath® Lung achieved 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value, and reports 7,783,061 common shares outstanding with an aggregate market value of approximately $5.1 million as of July 24, 2026.
Positive
- None.
Negative
- None.
Filing Explained
The filing states that CyPath® Lung is marketed as a Laboratory Developed Test and is not intended as a sole diagnostic tool; its proposed specialty pathways therefore supplement, rather than replace, clinical assessment and existing guidelines.
8-K Event Classification
Key Figures
Key Terms
pulmonary nodule medical
lung microenvironment medical
Laboratory Developed Test (LDT) regulatory
negative predictive value (NPV) medical
flow cytometry technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did bioAffinity Technologies (BIAF) report on July 27, 2026?
What is CyPath Lung and how does it work for bioAffinity Technologies (BIAF)?
What clinical trial performance metrics for CyPath Lung did BIAF highlight?
Which clinical settings are addressed in the new CyPath Lung framework from BIAF?
How does CyPath Lung differ from blood-based diagnostic tests according to BIAF?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
|
|
|
(Nasdaq Capital Market) | |
(Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On July 27, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing the publication of a comprehensive clinical review and white paper authored by the Company’s Chief Medical Officer, Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating CyPath® Lung into pulmonary nodule evaluation and cancer surveillance.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
As of July 24, 2026, there were 7,783,061 outstanding shares of the Company’s common stock and the aggregate market value of the Company’s common stock was approximately $5.1 million based on the closing price of a share of the Company’s common stock on that date, as reported by the Nasdaq Capital Market.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit Number |
Description | |
| 99.1 | Press Release issued by bioAffinity Technologies, Inc., dated July 27, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: July 27, 2026 | BIOAFFINITY TECHNOLOGIES, INC. | |
| By: | /s/ Maria Zannes | |
| Name: | Maria Zannes | |
| Title: | President and Chief Executive Officer | |
| -3- |
Exhibit 99.1
 |
 |
bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
Comprehensive clinical review outlines specialty-specific approaches for integrating the test’s lung microenvironment analysis into diagnostic pathway
Framework includes protocols for pulmonology, primary care and oncology practices for detection of lung cancer and surveillance of survivors
SAN ANTONIO, TX – July 27, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the publication of a comprehensive clinical review and white paper authored by Chief Medical Officer Gordon H. Downie, MD, PhD, that presents a practical clinical framework for incorporating CyPath® Lung into pulmonary nodule evaluation and cancer surveillance.
Titled “Lung Nodules, Lung Microenvironment, Predictive Models and Clinician Risk Stratification Using CyPath® Lung Testing for Early Diagnosis of Lung Cancer,” the paper examines the growing clinical challenge of evaluating pulmonary nodules as lung cancer screening expands, incidental findings increase, artificial intelligence identifies even more incidental nodules, and more patients require long-term surveillance following cancer treatment.
“Pulmonary medicine is entering a new era in which clinicians are evaluating more pulmonary nodules than ever before, driving a rapidly growing need for better risk stratification,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technologies. “Dr. Downie’s white paper demonstrates how CyPath® Lung can provide physicians with clinically meaningful information that complements imaging and clinical assessment, helping them make more confident decisions about which patients require invasive procedures and which can be safely monitored.”
Drawing on the three years of commercial experience since CyPath® Lung entered the market, the publication discusses how the noninvasive test has demonstrated consistent clinical performance in helping physicians stratify malignancy risk and guide patient management, including clinical case studies illustrating how CyPath® Lung helped clarify challenging cases in which imaging findings and predictive models alone produced uncertain or conflicting assessments.
The publication explores how advances in understanding the lung microenvironment are reshaping the evaluation of pulmonary nodules. Unlike blood-based diagnostics, CyPath® Lung analyzes sputum collected directly from the lungs, providing objective, real-time information from the lung microenvironment to help clarify complex or conflicting clinical presentations.
The paper also reviews the strengths and limitations of existing predictive models and emphasizes that no single diagnostic tool should be used in isolation. Instead, it proposes specialty-specific clinical pathways that integrate CyPath® Lung into three care settings:
| ● | Primary care practices managing incidentally discovered pulmonary nodules | |
| ● | Pulmonary nodule programs and interventional pulmonology practices evaluating patients for biopsy | |
| ● | Oncology practices conducting surveillance of cancer survivors |
“Every patient presents a unique clinical picture,” Dr. Downie said. “The objective is not to replace clinician gestalt or existing guidelines, but to provide an additional data point when clinical findings are uncertain or contradictory. CyPath® Lung’s interrogation of the lung microenvironment gives physicians information that has not previously been available through traditional imaging or blood-based testing.”
The white paper highlights the growing recognition that the lung possesses a unique microenvironment distinct from blood, reflecting local immune responses, inflammation, genetic alterations and tumor biology. By evaluating sputum directly from the lungs, CyPath® Lung measures these biologic changes and identifies porphyrin-labeled malignant cells through proprietary flow cytometry and artificial intelligence analysis.
The complete white paper is available at https://bit.ly/cypath-lung-whitepaper3
About CyPath® Lung
CyPath® Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath® Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath® Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to achieve physician adoption of the clinical framework and specialty-specific pathways described in the white paper, the assumption that expansion of lung cancer screening programs and increases in incidental pulmonary nodule findings will result in increased demand for CyPath® Lung, the Company’s ability to expand its customer base across pulmonology, primary care and oncology practices, the risk that competing diagnostic technologies including blood-based tests may achieve greater market acceptance, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Contact
bioAffinity Technologies
Julie Anne Overton
Director of Communications
investors@bioaffinitytech.com